AEROVATE THERAPEUTICS INC (AVTE) Stock Price, Quote, News and Overview
NASDAQ:AVTE - Nasdaq - US0080641071 - Common Stock - Currency: USD
AVTE Quote, Performance and Key Statistics
AEROVATE THERAPEUTICS INC
NASDAQ:AVTE (2/12/2025, 8:00:01 PM)
After market: 2.45 0 (0%)2.45
-0.02 (-0.81%)
The current stock price of AVTE is 2.45 USD. In the past month the price decreased by -1.83%. In the past year, price decreased by -88.28%.
AVTE Latest News and Analysis
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates MHLD, IPG, AVTE on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE, PFIE, EMKR on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PSTX, AVTE, GATO on Behalf of Shareholders
AVTE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.07 | 341.06B | ||
| AMGN | AMGEN INC | 14.89 | 158.60B | ||
| GILD | GILEAD SCIENCES INC | 22.41 | 128.75B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1562.76 | 116.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.55 | 72.95B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.81B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.82B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.80B | ||
| NTRA | NATERA INC | N/A | 22.70B | ||
| BIIB | BIOGEN INC | 8.17 | 19.44B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.28 | 16.55B |
Related stock screener links
About AVTE
Company Profile
Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Waltham, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH), a devastating disease impacting approximately 70,000 people in the United States and Europe. Oral imatinib also demonstrated statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in PAH patients. AV-101, delivered using a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. PAH is an orphan disease with unmet medical needs and is characterized by high pressure in the vessels transporting blood from the right side of the heart to the lungs.
Company Info
AEROVATE THERAPEUTICS INC
930 Winter Street, Suite M-500
Waltham MASSACHUSETTS US
CEO: Timothy P. Noyes
Employees: 51
Company Website: https://www.aerovatetx.com/
Investor Relations: https://ir.aerovatetx.com/
Phone: 16174432400
AVTE FAQ
What is the stock price of AVTE?
The current stock price of AVTE is 2.45 USD.
What is the symbol for AEROVATE THERAPEUTICS INC stock?
The exchange symbol of AEROVATE THERAPEUTICS INC is AVTE and it is listed on the Nasdaq exchange.
On which exchange is AVTE stock listed?
AVTE stock is listed on the Nasdaq exchange.
Is AVTE a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for AVTE, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of AVTE.
Does AVTE stock pay dividends?
AVTE does not pay a dividend.
What is the Price/Earnings (PE) ratio of AVTE?
AVTE does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.99).
What is the Short Interest ratio of AVTE stock?
The outstanding short interest for AVTE is 13.03% of its float.
AVTE Technical Analysis
AVTE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AVTE. AVTE has a great financial health rating, but its profitability evaluates not so good.
AVTE Financial Highlights
Over the last trailing twelve months AVTE reported a non-GAAP Earnings per Share(EPS) of -2.99. The EPS decreased by -8.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -93.02% | ||
| ROE | -105.12% | ||
| Debt/Equity | 0 |
AVTE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 49% to AVTE. The Buy consensus is the average rating of analysts ratings from 9 analysts.